Diligence memo · auto-generated · as of July 2, 2026
Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Marinus Pharmaceuticals, Inc. operates in Pharmaceuticals, based in Radnor.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Marinus Pharmaceuticals, Inc. has raised $73M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $30M on 2019-12-11.
Most recent recorded round closed around 2022-03-29.
Valuation (modeled)modeled
Provath models Marinus Pharmaceuticals, Inc. at approximately $21M (range $2.6M–$58M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.16× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 39 months.
Last raise 4.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 24.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 87% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 28% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.